TR201900649T4 - Oküler hastalıkların tedavisi için mrna tedavisi. - Google Patents

Oküler hastalıkların tedavisi için mrna tedavisi. Download PDF

Info

Publication number
TR201900649T4
TR201900649T4 TR2019/00649T TR201900649T TR201900649T4 TR 201900649 T4 TR201900649 T4 TR 201900649T4 TR 2019/00649 T TR2019/00649 T TR 2019/00649T TR 201900649 T TR201900649 T TR 201900649T TR 201900649 T4 TR201900649 T4 TR 201900649T4
Authority
TR
Turkey
Prior art keywords
treatment
mrna
ocular diseases
mrna therapy
eye
Prior art date
Application number
TR2019/00649T
Other languages
English (en)
Inventor
Calias Pericles
Derosa Frank
Heartlein Michael
Original Assignee
Translate Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54196241&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201900649(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Translate Bio Inc filed Critical Translate Bio Inc
Publication of TR201900649T4 publication Critical patent/TR201900649T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Mevcut buluş, diğer şeylerin yanı sıra, mesajcı RNA'nın (mRNA) oküler olarak verilmesine yönelik bir yöntem sunar; bu yöntem, bir proteini kodlayan mRNA içeren bir bileşimin, verilmesi gereken bir deneğin gözüne verilmesini içerir, böylece bileşimin uygulanması, gözdeki mRNA tarafından kodlanan proteinin ekspresyonuna yol açar.
TR2019/00649T 2014-03-24 2015-03-19 Oküler hastalıkların tedavisi için mrna tedavisi. TR201900649T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461969483P 2014-03-24 2014-03-24

Publications (1)

Publication Number Publication Date
TR201900649T4 true TR201900649T4 (tr) 2019-02-21

Family

ID=54196241

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/00649T TR201900649T4 (tr) 2014-03-24 2015-03-19 Oküler hastalıkların tedavisi için mrna tedavisi.

Country Status (15)

Country Link
US (2) US20170143848A1 (tr)
EP (3) EP3122878B1 (tr)
CY (1) CY1121348T1 (tr)
DK (2) DK3122878T3 (tr)
ES (2) ES2707969T3 (tr)
HR (1) HRP20190117T1 (tr)
HU (1) HUE041940T2 (tr)
LT (1) LT3122878T (tr)
ME (1) ME03314B (tr)
PL (1) PL3122878T3 (tr)
PT (1) PT3122878T (tr)
RS (1) RS58337B1 (tr)
SI (1) SI3122878T1 (tr)
TR (1) TR201900649T4 (tr)
WO (1) WO2015148247A1 (tr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2713852T3 (es) 2009-12-01 2019-05-24 Translate Bio Inc Derivado de esteroides para la administración de ARNm en enfermedades genéticas humanas
JP6022557B2 (ja) 2011-06-08 2016-11-09 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 切断可能な脂質
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
WO2017070613A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
IL258821B (en) 2015-10-23 2022-07-01 Harvard College Nucleobase editors and their uses
AU2016366978B2 (en) * 2015-12-10 2022-07-28 Modernatx, Inc. Compositions and methods for delivery of therapeutic agents
CA3010056A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
US20210206818A1 (en) 2016-01-22 2021-07-08 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
EP3442590A2 (en) 2016-04-13 2019-02-20 Modernatx, Inc. Lipid compositions and their uses for intratumoral polynucleotide delivery
SG11201900907YA (en) 2016-08-03 2019-02-27 Harvard College Adenosine nucleobase editors and uses thereof
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
GB2573062A (en) 2016-10-14 2019-10-23 Harvard College AAV delivery of nucleobase editors
JP6980780B2 (ja) 2016-10-21 2021-12-15 モデルナティーエックス， インコーポレイテッド ヒトサイトメガロウイルスワクチン
JP7121005B2 (ja) * 2016-11-23 2022-08-17 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 生物学的製剤の粒子媒介送達
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
WO2018157133A1 (en) 2017-02-27 2018-08-30 Translate Bio, Inc. Methods for purification of messenger rna
EP3585892B8 (en) 2017-02-27 2022-07-13 Translate Bio, Inc. Methods for purification of messenger rna
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
WO2018165629A1 (en) 2017-03-10 2018-09-13 President And Fellows Of Harvard College Cytosine to guanine base editor
CA3057192A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
AU2018270111B2 (en) 2017-05-18 2022-07-14 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
JP2020534795A (ja) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物
US20190300856A1 (en) * 2017-08-16 2019-10-03 Georgia Tech Research Corporation Messenger RNA based expression of opsins and reporter proteins for electrophysiologic characterization of in vitro neurons and cardiomyocytes
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
JP2021515808A (ja) * 2018-03-01 2021-06-24 ジョージア テック リサーチ コーポレイション ｍＲＮＡに基づく細胞表現型の調節および検出のための方法および組成物
CA3103436A1 (en) 2018-06-11 2019-12-19 The Regents Of The University Of California Demethylation to treat eye disease
CA3108544A1 (en) 2018-08-24 2020-02-27 Translate Bio, Inc. Methods for purification of messenger rna
GB2617429B (en) 2018-09-04 2023-12-27 Univ Texas Compositions and methods for organ specific delivery of nucleic acids
GB2606038B (en) 2018-09-04 2023-05-03 Univ Texas Compositions and methods for organ specific delivery of nucleic acids
CA3114699A1 (en) 2018-10-09 2020-04-16 The University Of British Columbia Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto
EP3877538A1 (en) 2018-11-08 2021-09-15 Translate Bio, Inc. Methods and compositions for messenger rna purification
WO2020097511A2 (en) * 2018-11-09 2020-05-14 Translate Bio, Inc. Messenger rna therapy for treatment of ocular diseases
AU2020206109A1 (en) * 2019-01-07 2021-07-29 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia
CA3125511A1 (en) * 2019-02-08 2020-08-13 Curevac Ag Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases
WO2020191153A2 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER
KR20230019843A (ko) 2020-05-08 2023-02-09 더 브로드 인스티튜트, 인코퍼레이티드 표적 이중 가닥 뉴클레오티드 서열의 두 가닥의 동시 편집을 위한 방법 및 조성물
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
WO2022099003A1 (en) 2020-11-06 2022-05-12 Sanofi Lipid nanoparticles for delivering mrna vaccines
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
JP2024515035A (ja) * 2021-04-01 2024-04-04 モデルナティエックス インコーポレイテッド ｍＲＮＡによる抗体構造及びアイソタイプの粘膜発現
IL309505A (en) 2021-09-03 2024-02-01 CureVac SE Lipid nanoparticles for nucleic acid delivery
WO2023073228A1 (en) 2021-10-29 2023-05-04 CureVac SE Improved circular rna for expressing therapeutic proteins
WO2023077148A1 (en) 2021-11-01 2023-05-04 Tome Biosciences, Inc. Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
WO2023122764A1 (en) 2021-12-22 2023-06-29 Tome Biosciences, Inc. Co-delivery of a gene editor construct and a donor template
WO2023144330A1 (en) 2022-01-28 2023-08-03 CureVac SE Nucleic acid encoded transcription factor inhibitors
WO2023205744A1 (en) 2022-04-20 2023-10-26 Tome Biosciences, Inc. Programmable gene insertion compositions
WO2023215831A1 (en) 2022-05-04 2023-11-09 Tome Biosciences, Inc. Guide rna compositions for programmable gene insertion
WO2023225670A2 (en) 2022-05-20 2023-11-23 Tome Biosciences, Inc. Ex vivo programmable gene insertion
WO2023227608A1 (en) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
WO2024020587A2 (en) 2022-07-22 2024-01-25 Tome Biosciences, Inc. Pleiopluripotent stem cell programmable gene insertion
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4401796A (en) 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
EP2292771A3 (en) * 1997-09-19 2011-07-27 Life Technologies Corporation Sense mRNA therapy
US7507859B2 (en) * 2003-06-16 2009-03-24 Fifth Base Llc Functional synthetic molecules and macromolecules for gene delivery
AU2005252273B2 (en) 2004-06-07 2011-04-28 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
BRPI0610499A2 (pt) * 2005-04-12 2010-06-22 Intradigm Corp moléculas de ácido nucléico , composições e usos das referidas moléculas
EP2266656B1 (en) 2005-04-18 2020-10-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Devices for delivering a biologically active agent to the ocular sphere of a subject
EP2049665A2 (en) 2006-07-28 2009-04-22 Applera Corporation Dinucleotide mrna cap analogs
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
US20090011040A1 (en) * 2007-05-02 2009-01-08 Naash Muna I Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
WO2009058911A2 (en) 2007-10-31 2009-05-07 Applied Biosystems Inc. Preparation and isolation of 5' capped mrna
EP2350043B9 (en) 2008-10-09 2014-08-20 TEKMIRA Pharmaceuticals Corporation Improved amino lipids and methods for the delivery of nucleic acids
US8969353B2 (en) 2008-11-07 2015-03-03 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
ES2713852T3 (es) * 2009-12-01 2019-05-24 Translate Bio Inc Derivado de esteroides para la administración de ARNm en enfermedades genéticas humanas
US8889193B2 (en) 2010-02-25 2014-11-18 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
US9019345B2 (en) 2010-07-02 2015-04-28 Intuitive Surgical Operations, Inc. Imaging mode blooming suppression
US8853377B2 (en) * 2010-11-30 2014-10-07 Shire Human Genetic Therapies, Inc. mRNA for use in treatment of human genetic diseases
ES2385080B1 (es) 2010-12-21 2013-05-10 Universidad Del Pais Vasco-Euskal Herriko Unibertsitatea Nanopartículas lipídicas para el tratamiento de enfermedades oculares.
IL280771B2 (en) 2011-06-08 2024-03-01 Shire Human Genetic Therapies Preparations of lipid nanoparticles and methods for administration of mRNA
JP6022557B2 (ja) 2011-06-08 2016-11-09 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 切断可能な脂質
NZ747501A (en) 2011-10-27 2020-05-29 Massachusetts Inst Technology Amino acid derivatives functionalized on the n-terminal capable of forming drug encapsulating microspheres
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
EP2607375A1 (en) 2011-12-21 2013-06-26 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Variants of yeast NDI1 gene, and uses thereof in the treatment of disease associated with mitochondrial dysfunction.
AU2013237873B2 (en) * 2012-03-29 2017-12-14 Translate Bio, Inc. Ionizable cationic lipids
EP3865123A1 (en) * 2012-03-29 2021-08-18 Translate Bio, Inc. Lipid-derived neutral nanoparticles
AU2013243953A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of nuclear proteins
TWI698240B (zh) * 2012-05-15 2020-07-11 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
EA201591293A1 (ru) * 2013-03-14 2016-02-29 Шир Хьюман Дженетик Терапис, Инк. Способы и композиции для доставки антител, кодируемых мрнк
EA034103B1 (ru) * 2013-10-22 2019-12-27 Транслейт Био, Инк. СПОСОБ ЛЕЧЕНИЯ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК
PE20161242A1 (es) * 2013-10-22 2016-12-11 Massachusetts Inst Technology Formulaciones de lipidos para la administracion de arn mensajero

Also Published As

Publication number Publication date
CY1121348T1 (el) 2020-05-29
EP3699274A1 (en) 2020-08-26
DK3122878T3 (en) 2019-02-04
DK3450553T3 (da) 2020-02-10
RS58337B1 (sr) 2019-03-29
PT3122878T (pt) 2019-02-01
EP3122878A4 (en) 2017-08-30
ME03314B (me) 2019-10-20
ES2707969T3 (es) 2019-04-08
HUE041940T2 (hu) 2019-06-28
US20220354968A1 (en) 2022-11-10
EP3450553B1 (en) 2019-12-25
US20170143848A1 (en) 2017-05-25
SI3122878T1 (sl) 2019-05-31
HRP20190117T1 (hr) 2019-04-19
ES2774552T3 (es) 2020-07-21
WO2015148247A1 (en) 2015-10-01
EP3122878B1 (en) 2018-10-24
PL3122878T3 (pl) 2019-06-28
EP3450553A1 (en) 2019-03-06
EP3122878A1 (en) 2017-02-01
LT3122878T (lt) 2019-02-11

Similar Documents

Publication Publication Date Title
TR201900649T4 (tr) Oküler hastalıkların tedavisi için mrna tedavisi.
EA202090919A1 (ru) Липидные наночастицы для доставки модифицированной рнк, кодирующей полипептид vegf-a
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
NZ718817A (en) Lipid formulations for delivery of messenger rna
MX2017007321A (es) Terapias de combinacion.
EA201690588A1 (ru) Доставка мрнк в цнс и ее применение
PH12019501339A1 (en) Amino acid compositions and methods for the treatment of muscle diseases and disorders
SG10201810888XA (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
MX2019000586A (es) Virus adenoasociados (aav) sflt-1 para usarse en el tratamiento de degeneración macular relacionada con la edad (amd).
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
JO3784B1 (ar) الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
WO2020097511A3 (en) Messenger rna therapy for treatment of ocular diseases
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
MX2015011846A (es) Proteinas de sustancia de inhibicion mulleriana (mis) modificadas y sus usos para el tratamiento de enfermedades.
EA201890815A1 (ru) Аминокислотные композиции с модифицированным высвобождением для перорального введения
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201501054A1 (ru) Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы
MX2018015110A (es) Arn modificado que codifica polipeptidos de vegf-a. formulaciones y usos relacionados con los mismos.
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
EA201691567A1 (ru) Способы лечения легких травм головного мозга
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EA201790223A1 (ru) Водный препарат, содержащий парацетамол и ибупрофен
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.